2008
DOI: 10.1001/archderm.144.5.658
|View full text |Cite
|
Sign up to set email alerts
|

Improvement of Intravenous Immunoglobulin Therapy for Bullous Pemphigoid by Adding Immunosuppressive Agents

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2010
2010
2018
2018

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 15 publications
(2 citation statements)
references
References 22 publications
0
2
0
Order By: Relevance
“…IVIg, 2 g/kg/month, was given on 4–5 consecutive days as a slow, approximately 4‐hour infusion, hereinafter referred to as “IVIg cycle.” Prior to each infusion, the patients were premedicated with 50 mg diphenhydramine and 500 mg acetaminophen. To prevent a rebound effect from compensatory overproduction of pemphigus antibodies by the autoantibody‐producing cells stimulated via a negative feedback due to rapid clearance of pathogenic IgGs, IVIg was combined with the ICD mycophenolate mofetil 2 g/day, azathioprine 200 mg/day, or cyclophosphamide 150 mg/day, chosen in the above order depending on the patient's insurance allowance as well as counter‐indications and adverse reactions (Fig. a).…”
Section: Treatment Protocolmentioning
confidence: 99%
“…IVIg, 2 g/kg/month, was given on 4–5 consecutive days as a slow, approximately 4‐hour infusion, hereinafter referred to as “IVIg cycle.” Prior to each infusion, the patients were premedicated with 50 mg diphenhydramine and 500 mg acetaminophen. To prevent a rebound effect from compensatory overproduction of pemphigus antibodies by the autoantibody‐producing cells stimulated via a negative feedback due to rapid clearance of pathogenic IgGs, IVIg was combined with the ICD mycophenolate mofetil 2 g/day, azathioprine 200 mg/day, or cyclophosphamide 150 mg/day, chosen in the above order depending on the patient's insurance allowance as well as counter‐indications and adverse reactions (Fig. a).…”
Section: Treatment Protocolmentioning
confidence: 99%
“…In addition to pemphigus, we have studied the effect of IVIg in combination with a cytotoxic agent in a 78‐year‐old patient with autoantibody‐mediated bullous pemphigoid . The patient had multiple cycles of IVIg treatment, with or without immunosuppressants on an alternating schedule, over a period of 20 months.…”
mentioning
confidence: 99%